Onesource Specialty Pharma
ONESOURCE •NSE

Onesource Specialty Pharma

₹1,563.00-6.60 (0.42%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
1,540.90
Today’s high
1,600.00
52 week low
1,057.00
52 week high
1,925.00
Open price
1,574.80
Previous close
1,569.60
Live volume
9,54,663
Lower circuit
1,250.40
Upper circuit
1,875.60

Fundamentals

Market Cap
₹18,000Cr
ROE
0.19%
P/E Ratio(TTM)
--
EPS(TTM)
-0.14
P/B Ratio
3.04
Dividend Yield
0.00%
Industry P/E
37.65
Book Value
516.32
Debt to Equity
0.30
Face Value
1

Financial performance

Quarterly
Yearly
All Financials
SEP '26
₹517Cr
+14.22%
₹57.48Cr
+129.92%
-2000200400600
Sep '25
Dec '25
Mar '26
Jun '26
Sep '26
Revenue growthValue
1Y (TTM)+37%
3Y CAGR+226%
Profit growthValue
1Y (TTM)+448%
3Y CAGR+78%

About

Onesource Specialty Pharma Limited is a contract development and manufacturing organization (CDMO) for complex injectables and biologics.;
CEO/MD
Neeraj Sharma
Founded in
2007
NSE symbol
ONESOURCE
Industry

Shareholding pattern

Sep '25
Dec '25
Mar '26
Jun '26
Sep '26
Shareholder details

Mutual Funds Invested (4)

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
₹19,700.00
+420.00 (2.18%)
L
    H
    24,730.8349.6813.2
    ₹444.30
    -37.05 (7.70%)
    L
      H
      18,416.32314.614.71
      ₹402.70
      +4.10 (1.03%)
      L
        H
        16,078.1486.43.31
        ₹731.70
        -9.35 (1.26%)
        L
          H
          11,664.4739.843.52
          Livesquawk •
          OneSource received a USFDA Establishment Inspection Report (EIR) with VAI status. The report concludes the inspection at its Bengaluru sterile product division facility.
          Livesquawk •
          Onesource Specialty expects semaglutide approvals in Brazil and Turkey within the next two quarters. The expected approvals could potentially support future revenue growth opportunities for the company.
          Livesquawk •
          Onesource reported a strong YoY jump in Q2 standalone net profit to ₹862M versus ₹371M.
          2026
          27
          Oct
          Quarterly Result
          Release date
          24
          Jul
          Quarterly Result
          Release date
          13
          May
          Annual Result
          Release date
          23
          Jan
          Quarterly Result
          Release date
          2025
          11
          Nov
          Quarterly Result
          Release date
          4
          Aug
          Quarterly Result
          Release date
          Events calendar
          View upcoming events in other stocks